47 results on '"Selcuklu, S. Duygu"'
Search Results
2. Tumour lineage shapes BRCA-mediated phenotypes
3. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
4. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
5. Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
6. Data from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
7. Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
8. Supplementary Figure S2 from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
9. Data from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
10. Supplementary Figures from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
11. Supplementary Data from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
12. Supplementary Methods from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
13. Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
14. Author Correction: Tumour lineage shapes BRCA-mediated phenotypes
15. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers
16. Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trial
17. ALCAM is indirectly modulated by miR-125b in MCF7 cells
18. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis
19. HER kinase inhibition in patients with HER2- and HER3-mutant cancers
20. Additional file 2 of Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients
21. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
22. Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs
23. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
24. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
25. Author Correction: Tumour lineage shapes BRCA-mediated phenotypes
26. Abstract 1752: BRCA-mediated tumorigenesis is origin and cell-type dependent
27. Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
28. Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.
29. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
30. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
31. Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition
32. Abstract 5533: Cell-free DNA sequencing in ERBB2-mutant breast cancer patients treated with neratinib and fulvestrant: Exploratory analysis from the Phase 2 SUMMIT ‘basket' trial
33. Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).
34. AKT Inhibition in Solid Tumors With AKT1 Mutations
35. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
36. Allele-specific splicing effects on DKKL1 and ZNF419 transcripts in HeLa cells
37. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma
38. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid
39. Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363).
40. ALCAM is indirectly modulated by miR-125b in MCF7 cells
41. An NTD-Associated Polymorphism in the 3′ UTR of MTHFD1L can Affect Disease Risk by Altering miRNA Binding
42. Regulatory interplay between miR-21, JAG1 and 17beta-estradiol (E2) in breast cancer cells
43. miR-21 as a key regulator of oncogenic processes
44. Translational Epigenetics: Clinical Approaches to Epigenome Therapeutics for Cancer
45. An NTD-Associated Polymorphism in the 3′ UTR of MTHFD1 L can Affect Disease Risk by Altering mi RNA Binding.
46. MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells.
47. An NTD-associated polymorphism in the 3' UTR of MTHFD1L can affect disease risk by altering miRNA binding.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.